R Squared Ltd grew its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 8,266.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,530 shares of the medical equipment provider's stock after buying an additional 7,440 shares during the period. Boston Scientific makes up 0.8% of R Squared Ltd's holdings, making the stock its 17th biggest position. R Squared Ltd's holdings in Boston Scientific were worth $760,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG grew its holdings in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after buying an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Boston Scientific in the first quarter valued at about $8,234,000. Blue Trust Inc. boosted its stake in Boston Scientific by 13.0% in the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after buying an additional 575 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S boosted its stake in Boston Scientific by 109.9% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock valued at $24,126,000 after buying an additional 141,398 shares in the last quarter. Institutional investors own 89.07% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on BSX. UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Truist Financial lifted their price target on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Raymond James Financial lifted their price target on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Robert W. Baird lifted their price target on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Finally, Oppenheimer lifted their price target on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and a consensus target price of $117.50.
Get Our Latest Stock Analysis on BSX
Boston Scientific Stock Up 1.3%
Shares of NYSE:BSX traded up $1.33 during mid-day trading on Monday, hitting $106.74. 4,623,589 shares of the company traded hands, compared to its average volume of 7,770,241. The stock has a market cap of $157.92 billion, a P/E ratio of 63.54, a P/E/G ratio of 2.54 and a beta of 0.66. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $108.94. The stock has a 50-day moving average price of $103.63 and a two-hundred day moving average price of $101.93.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The business's revenue was up 22.8% on a year-over-year basis. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Insiders Place Their Bets
In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is currently owned by insiders.
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Recommended Stories

Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report